Understanding how proteins interact and their roles in diseases
Official title: Computational and Experimental Investigation and Design of Protein Interaction Specificity
Funded at Massachusetts Institute of Technology · NIH-11092108 · Data updated 2026-11-12
This study is looking at how proteins in our cells work together and how these interactions can change when someone has cancer, with the goal of finding new ways to treat diseases by understanding and possibly changing these protein connections.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts Institute of Technology NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project start | June 1, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $541,050 |
| NIH project number | 5R35GM149227-03 |
| Project ID | NIH-11092108 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with conditions related to protein interaction abnormalities, such as cancer or other diseases influenced by cellular signaling.
✕Less likely to help
Patients with conditions unrelated to protein interactions or those not involving cellular signaling pathways may not benefit from this research.
What this research studies
This research investigates the complex interactions between proteins that are crucial for cellular functions and how these interactions can change in diseases like cancer. By combining computational methods and experimental techniques, the study aims to map the human interactome, which is the network of protein interactions, and identify specific binding motifs that play significant roles in cellular signaling and structure. The research will also explore how to inhibit or modulate these interactions to develop new therapeutic strategies. Patients may benefit from insights gained about protein interactions that could lead to innovative treatments for various diseases.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that target specific protein interactions involved in diseases, potentially improving treatment outcomes for patients.
How similar studies have gone: Other research has shown success in understanding protein interactions and their implications in diseases, indicating that this approach has potential for significant advancements.
Where this research is happening
-
Massachusetts Institute of Technology
Cambridge, United States Active
Researchers
- Principal investigator: Keating, Amy E — Massachusetts Institute of Technology
- Study coordinator: Keating, Amy E
Related research
Other NIH-funded projects on the same topics.
-
PhysioNet: A trusted, open data repository for clinical and physiological data
A publicly accessible platform provides curated clinical and physiological data and tools to help researchers develop and test AI models for better healthcare.
-
Dormancy in Triple-Negative Breast Cancer: How Liver and Skin Metastases Go Quiet or Reactivate
Researchers will study how dormant cancer cells in liver and skin metastases of triple-negative breast cancer become quiescent or wake up, using organ-on-chip models and single-cell analysis to map chromatin states.
-
Single-cell, label-free mapping of senescence in tissues with Raman imaging and spatial genomics
A project to map how senescent cells differ across tissues using a noninvasive Raman imaging method combined with spatial genomics.
-
Structures and dynamics of virus ion channels
This project studies the tiny channels in certain influenza and coronavirus viruses to understand how they let ions pass through and contribute to disease.
-
Prospect: Stem Cell Models for Early-Onset Colorectal Cancer Prevention
Researchers at MIT are using stem cell models to understand why colorectal cancer is rising in people under 50 and how to prevent it.
-
MATCHMAKERS: AI tools to predict TCR binding and design
Researchers are building AI tools to predict how T cell receptors recognize tumor antigens, with aims to help improve targeted immunotherapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.